Last reviewed · How we verify

NCT04599712

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

APPROVED FOR MARKETING Last updated 13 June 2025
What this trial tests

trial testing Amivantamab in Metastatic Non-Small Cell Lung Cancer. Approved for marketing.

Quick facts

Lead sponsorJanssen Research & Development, LLC
StatusAPPROVED FOR MARKETING
Study typeEXPANDED_ACCESS

Drugs / interventions tested

Conditions studied

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, any sex, with Metastatic Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this expanded access program (EAP) is to provide amivantamab for the treatment of participants with metastatic non-small cell lung cancer who have epidermal growth factor receptor exon 20 insertion mutations, and whose disease has progressed during or after current standard of care platinum-based chemotherapy. This intermediate EAP may be considered for individuals with serious/life-threatening diseases or conditions, where there are no alternative treatments or where individuals have progressed following standard of care.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Tumor biomarkers for diagnosis, prognosis and targeted therapy.
    Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
  2. Recent advances and challenges of bispecific antibodies in solid tumors.
    Wu Y, Yi M, Zhu S, Wang H, et al · · 2021 · cited 64× · PMID 34922633 · DOI 10.1186/s40164-021-00250-1
  3. Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.
    Neuendorf HM, Simmons JL, Boyle GM. · · 2023 · cited 18× · PMID 37181747 · DOI 10.3389/fcell.2023.1183328
  4. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors.
    Gu Y, Zhao Q. · · 2024 · cited 16× · PMID 39172329 · DOI 10.1007/s40291-024-00734-w
  5. Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials.
    Yu L, Yang R, Long Z, Tao Q, et al · · 2024 · cited 12× · PMID 39391239 · DOI 10.3389/fonc.2024.1451230
  6. Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding.
    Shaw P, Dey Bhowmik A, Gopinatha Pillai MS, Robbins N, et al · · 2025 · cited 11× · PMID 40294841 · DOI 10.1016/j.canlet.2025.217750
  7. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.
    Petrini I, Giaccone G. · · 2022 · cited 7× · PMID 36246734 · DOI 10.2147/ott.s329095
  8. Amivantamab: A Novel Advance in the Treatment of Non-small Cell Lung Cancer.
    Zavaleta-Monestel E, García-Montero J, Arguedas-Chacón S, Quesada-Villaseñor R, et al · · 2024 · cited 2× · PMID 38910714 · DOI 10.7759/cureus.60851

Verify or expand the search:

Other trials of Amivantamab

Trials testing the same drug.

Other recruiting trials for Metastatic Non-Small Cell Lung Cancer

Currently open trials in the same condition.

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04599712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing